MX2024000544A - Superacion de la interferencia de los anticuerpos en las aves. - Google Patents
Superacion de la interferencia de los anticuerpos en las aves.Info
- Publication number
- MX2024000544A MX2024000544A MX2024000544A MX2024000544A MX2024000544A MX 2024000544 A MX2024000544 A MX 2024000544A MX 2024000544 A MX2024000544 A MX 2024000544A MX 2024000544 A MX2024000544 A MX 2024000544A MX 2024000544 A MX2024000544 A MX 2024000544A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- antibody
- interference
- antigen
- recombinant protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21185334 | 2021-07-13 | ||
| PCT/EP2022/069513 WO2023285489A1 (en) | 2021-07-13 | 2022-07-12 | Overcoming antibody-interference in avians |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000544A true MX2024000544A (es) | 2024-04-09 |
Family
ID=76920583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000544A MX2024000544A (es) | 2021-07-13 | 2022-07-12 | Superacion de la interferencia de los anticuerpos en las aves. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250009868A1 (https=) |
| EP (1) | EP4370150A1 (https=) |
| JP (1) | JP2024525697A (https=) |
| CN (1) | CN117881422A (https=) |
| MX (1) | MX2024000544A (https=) |
| WO (1) | WO2023285489A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961982A (en) | 1985-09-06 | 1999-10-05 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
| FR2749022B1 (fr) | 1996-05-23 | 2001-06-01 | Rhone Merieux | Cellules aviaires immortelles |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| JP5432703B2 (ja) | 2006-03-15 | 2014-03-05 | インターベツト・インターナシヨナル・ベー・ベー | 組み換えモノネガウイルス目ウイルスベクター |
| EP2414386B1 (en) | 2009-04-03 | 2016-01-27 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| CN103370079B (zh) | 2010-10-18 | 2016-08-10 | 英特维特国际股份有限公司 | 针对家禽中禽流感的火鸡疱疹病毒作为载体的疫苗 |
| US9012424B2 (en) | 2011-05-27 | 2015-04-21 | 20Med Therapeutics B.V. | Nanogels |
| US10428316B2 (en) | 2014-12-04 | 2019-10-01 | Intervet Inc. | Immortalised chicken embryo fibroblasts |
| JP2018527395A (ja) | 2015-09-30 | 2018-09-20 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | 改良モジュール型抗原移送分子及び動物におけるその使用 |
| MX2020005584A (es) | 2017-12-04 | 2020-09-14 | Intervet Int Bv | Vacunacion con particulas de replicon y adyuvante oleoso. |
| WO2019121888A1 (en) | 2017-12-20 | 2019-06-27 | Intervet International B.V. | Improved diluent for cell-associated alphaherpesvirus vaccine |
| GB202016954D0 (en) * | 2020-10-26 | 2020-12-09 | Pirbright Inst | Vaccine |
-
2022
- 2022-07-12 MX MX2024000544A patent/MX2024000544A/es unknown
- 2022-07-12 WO PCT/EP2022/069513 patent/WO2023285489A1/en not_active Ceased
- 2022-07-12 EP EP22751050.0A patent/EP4370150A1/en active Pending
- 2022-07-12 JP JP2024501558A patent/JP2024525697A/ja active Pending
- 2022-07-12 US US18/576,496 patent/US20250009868A1/en active Pending
- 2022-07-12 CN CN202280049751.5A patent/CN117881422A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4370150A1 (en) | 2024-05-22 |
| US20250009868A1 (en) | 2025-01-09 |
| WO2023285489A1 (en) | 2023-01-19 |
| CN117881422A (zh) | 2024-04-12 |
| JP2024525697A (ja) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103162A1 (es) | Anticuerpos anti-c5 y métodos para su uso | |
| CL2022001375A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y usos de los mismos | |
| MX2021000193A (es) | Selección de epítopos de vacunas personalizadas contra el cáncer. | |
| CR20190013A (es) | Anticuerpos anti-c5 y métodos de uso | |
| CR20200461A (es) | Método para tratar las enfermedades asociadas al vph | |
| ECSP21052180A (es) | Receptores que ofrecen coestimulación específica para terapia adoptiva de células | |
| CO2018007374A2 (es) | Anticuerpos anti-c5 y métodos de uso | |
| CO2020015167A2 (es) | Variante de antígeno de virus de varicela zóster y uso de la misma | |
| MX2021011816A (es) | Metodos para produccion de celulas car-nk y uso de las mismas. | |
| MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
| CL2021001034A1 (es) | Métodos y composiciones para terapia con células oculares | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| MX2017003268A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
| CL2021002727A1 (es) | Vacuna con subunidades del vfpc | |
| MX2017004275A (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| CO2022006014A2 (es) | Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas | |
| CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
| MX2017012284A (es) | Nuevos metodos para la seleccion de epitopos. | |
| CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| MX2020013772A (es) | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. | |
| MX2020005836A (es) | Controles sinteticos para inmunohistoquimica. | |
| MX2021008035A (es) | Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña. | |
| MX2024000544A (es) | Superacion de la interferencia de los anticuerpos en las aves. | |
| MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. |